Douglas A. McClain, Jr. Resumes CFO Duties at Immunosyn
February 01 2008 - 4:41PM
PR Newswire (US)
LA JOLLA, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Immunosyn
Corporation (OTC:IMYN) (BULLETIN BOARD: IMYN) has announced that
Douglas A. McClain, Jr., will resume the duties of CFO effective
February 1, 2008. Mr. McClain also serves as the Company's Chairman
of the Board and Corporate Secretary. At the same time Immunosyn
announced the resignation of G. David Criner as the company's Chief
Financial and Accounting Officer. Mr. Criner, hired in October
2007, is leaving due to family matters. "We appreciated David's
expertise through this first leg of our development and welcome
Douglas A. McClain, Jr. back in his former role as CFO. In the
interim we have initiated a candidate search for a permanent CFO,"
commented Stephen D. Ferrone, CEO and President of Immunosyn
Corporation. About Immunosyn Corporation La Jolla, CA-headquartered
Immunosyn Corporation (OTC:IMYN) (BULLETIN BOARD: IMYN) plans to
market and distribute life enhancing therapeutics. Currently, the
company has exclusive worldwide rights from its largest
shareholder, Argyll Biotechnologies, LLC, to market, sell and
distribute SF-1019, a compound that was developed from extensive
research into Biological Response Modifiers (BRMs). Argyll
Biotechnologies, LLC has initiated the process for regulatory
approval of SF-1019 in several countries and preparations for
clinical trials are underway in both the US and Europe. Research
suggests that SF-1019 has the potential to affect a number of
clinical conditions including auto-immune disorders such as
Multiple Sclerosis (MS), neurological disorders such as Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex
Sympathetic Dystrophy Syndrome (RSD or RSDS) and complications from
Diabetic Mellitus such as Diabetic Neuropathy (DN) and Diabetic
Ulcers (DU). Except for the historical information contained
herein, this press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements speak
only as of the date on which such statements are made and involve
risks and uncertainties detailed in the Company's filings with the
Securities and Exchange commission, including risks summarized in
the company's annual Report of form 10-K for its most recent fiscal
year. The Company's actual results could differ materially from
such forward-looking statements. The Company undertakes no
obligation to update any forward-looking statement or statements to
reflect new events or circumstances or future developments.
DATASOURCE: Immunosyn Corporation CONTACT: Bill Kraus, Lisa Baker
or Devon Blaine, all of The Blaine Group, +1-310-360-1499, fax,
+1-310-360-1498, , for Immunosyn Corporation
Copyright